Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Sees Significant Decrease in Short Interest

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was the target of a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 1,080,000 shares, a decrease of 5.3% from the May 15th total of 1,140,000 shares. Approximately 9.5% of the shares of the company are sold short. Based on an average trading volume of 151,900 shares, the short-interest ratio is presently 7.1 days.

Eagle Pharmaceuticals Stock Up 5.5 %

NASDAQ EGRX opened at $4.06 on Tuesday. Eagle Pharmaceuticals has a 52 week low of $3.21 and a 52 week high of $23.52. The firm has a market capitalization of $52.74 million, a P/E ratio of 3.44 and a beta of 0.45. The company has a 50-day moving average price of $4.24 and a 200-day moving average price of $5.00.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Eagle Pharmaceuticals in a research note on Friday. They set a “hold” rating on the stock.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Connors Investor Services Inc. grew its holdings in Eagle Pharmaceuticals by 24.8% during the 3rd quarter. Connors Investor Services Inc. now owns 12,566 shares of the specialty pharmaceutical company’s stock valued at $198,000 after buying an additional 2,500 shares in the last quarter. Vanguard Group Inc. grew its holdings in Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after buying an additional 2,630 shares in the last quarter. Headlands Technologies LLC grew its holdings in Eagle Pharmaceuticals by 75.7% during the 1st quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 2,861 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Eagle Pharmaceuticals by 623.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,841 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 5,896 shares in the last quarter. Finally, DGS Capital Management LLC purchased a new stake in Eagle Pharmaceuticals during the 4th quarter valued at approximately $60,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.